PropertyValue
?:abstract
  • Pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus 19 disease (COVID-19) which presents a large spectrum of manifestations with fatal outcomes in vulnerable people over 70-years-old and with hypertension, diabetes, obesity, cardiovascular disease, COPD, and smoking status. Knowledge of the entry receptor is key to understand SARS-CoV-2 tropism, transmission and pathogenesis. Early evidence pointed to angiotensin-converting enzyme 2 (ACE2) as SARS-CoV-2 entry receptor. Here, we provide a critical summary of the current knowledge highlighting the limitations and remaining gaps that need to be addressed to fully characterize ACE2 function in SARS-CoV-2 infection and associated pathogenesis. We also discuss ACE2 expression and potential role in the context of comorbidities associated with poor COVID-19 outcomes. Finally, we discuss the potential co-receptors/attachment factors such as neuropilins, heparan sulfate and sialic acids and the putative alternative receptors, such as CD147 and GRP78.
is ?:annotates of
?:creator
?:doi
  • 10.7554/elife.61390
?:doi
?:journal
  • eLife
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/5823fb78a92289a2f99b72b597055ed349fd49ba.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7652413.xml.json
?:pmcid
?:pmid
?:pmid
  • 33164751.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities
?:type
?:year
  • 2020-11-09

Metadata

Anon_0  
expand all